Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792143 | 0.86 | CCR1 (0.51) | CCR1KMT2ANPC1CRHBPCRHR2 | |
| SCHEMBL4776970 | 0.84 | ADORA1 (0.44) | CCR1ADORA1KMT2AMC4RMAPK1 | |
| SCHEMBL4794341 | 0.83 | KMT2A (0.44) | CCR1ADORA1KMT2ACTSSCTSK | |
| SCHEMBL4793703 | 0.80 | KMT2A (0.56) | CCR1KMT2ACTSSCTSKCTSB | |
| SCHEMBL4794672 | 0.80 | KMT2A (0.56) | CCR1KMT2ACTSSCTSKCTSB | |
| SCHEMBL4770788 | 0.80 | AKT1 (0.52) | CCR1KMT2ACNR1 | |
| SCHEMBL4771069 | 0.80 | AKT1 (0.52) | CCR1KMT2ACNR1 | |
| SCHEMBL15810045 | 0.77 | HRH2 (0.58) | KMT2ACTSSCTSKCTSBMC4R | |
| SCHEMBL4510471 | 0.77 | MC4R (0.56) | CCR1KMT2ACTSSCTSKMC4R | |
| SCHEMBL5064576 | 0.77 | HRH2 (0.58) | KMT2ACTSSCTSKCTSBMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | CCR1 2053/4885ADORA1 809/4885KMT2A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.